Mayo Clinic researchers have identified a novel function of the NKG7 protein in regulating cellular resistance and combating tumors in certain cancers, offering promising avenues for improved cancer treatments and patient outcomes. This protein, found within CD8+ T cells—immune cells capable of recognizing and destroying cancer cells—enhances the resilience of these T cells, enabling them to continue attacking cancer cells even under stressful conditions.
The study, detailed in Nature Communications, reveals that NKG7 helps prevent cancer growth and metastasis by sustaining CD8+ T cell activity.
Clinical Significance of NKG7 Expression
The research team observed that invasive bladder cancer patients with NKG7-expressing CD8+ T cells infiltrating their tumors exhibited higher survival rates compared to those without such cells. Senior author Dr. Dan Billadeau emphasizes that this discovery opens possibilities for enhancing T cell-based therapies like CAR-T and tumor-infiltrating lymphocyte (TIL) therapies.
Despite advances in these treatments, many patients experience only short-term responses before cancer progresses, highlighting the need for strategies to prolong therapeutic efficacy.
Mechanism of Action Unveiled
NKG7 operates within lysosomes—cellular organelles—to suppress overactivation of mTOR, a protein regulating cell growth that often limits the persistence of functional CD8+ T cells. By moderating mTOR activity, NKG7 extends the lifespan of effector CD8+ T cells, which is critical for controlling cancer progression.
This mechanism, previously linked to durable responses in melanoma patients undergoing anti-PD-1 immunotherapy, now finds clearer biological explanation through Mayo Clinic’s latest work.
Therapeutic Applications and Predictive Potential
The findings suggest that modulating NKG7 expression could enhance the effectiveness of CAR-T and TIL therapies. In CAR-T therapy, T cells are engineered to express chimeric antigen receptors targeting cancer cells, while TIL therapy involves expanding tumor-derived T cells for reinfusion.
Incorporating NKG7 may grant these cells a more resilient phenotype, improving long-term outcomes. Additionally, NKG7 levels in CD8+ T cells within tumors or peripheral blood could serve as biomarkers to predict responses to immune checkpoint inhibitors, though further validation is required.
Future Research Directions
Mayo Clinic’s team is advancing multiple projects to integrate NKG7 into T cell therapies, currently testing these enhancements in animal models. Concurrently, they are investigating NKG7’s prognostic value across other cancers, exploring how CD8+/NKG7+ T cell ratios correlate with survival and treatment responses.
These efforts aim to translate laboratory insights into clinical strategies that amplify the body’s innate ability to fight cancer.
Related topics
